# QLS5132 Combination Therapy in Advanced Solid Tumors

> **NCT07453394** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Qilu Pharmaceutical Co., Ltd.** · enrollment: 626 (estimated)

## Conditions studied

- Gastric Cancer (GC)
- Non-small Cell Lung Cancer (NSCLC)
- Endometrial Cancer
- Advanced Solid Tumors
- Ovarian Cancer

## Interventions

- **DRUG:** QLS5132; Bevacizumab
- **DRUG:** QLS5132; Platinum; Bevacizumab
- **DRUG:** QLS5132; Olaparib; Bevacizumab
- **DRUG:** QLS5132; QL1706; QL2107
- **DRUG:** QLS5132; QL1706; QL2107; Carboplatin; Cisplatin; Oxaliplatin

## Key facts

- **NCT ID:** NCT07453394
- **Lead sponsor:** Qilu Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04
- **Primary completion:** 2027-04
- **Final completion:** 2029-02
- **Target enrollment:** 626 (ESTIMATED)
- **Last updated:** 2026-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07453394

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07453394, "QLS5132 Combination Therapy in Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07453394. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*